or Try an Advanced Search...

    Technical Analysis for GALT - Galectin Therapeutics Inc.

    Grade Last Price % Change Price Change
    F 2.50 1.21% 0.03
    GALT closed up 1.21 percent on Friday, November 1, 2024, on 85 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: Nov 11
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical GALT trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.00%
    Doji - Bullish? Reversal 0.00%
    Gapped Up Strength 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    200 DMA Resistance Bearish 1.21%
    Oversold Stochastic Weakness 1.21%
    20 DMA Resistance Bearish -0.79%
    50 DMA Resistance Bearish -0.79%
    Fell Below 200 DMA Bearish -0.79%
    Older End-of-Day Signals for GALT ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Resistance about 19 hours ago
    200 DMA Resistance about 21 hours ago
    Up 2% about 21 hours ago
    Up 1% about 21 hours ago
    200 DMA Resistance 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    GALT Chart by TradingView
    Basic chart:

    Profile

    Galectin Therapeutics Inc., a development stage company, engages in the development of therapies for cancer and fibrotic disease. Its lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trial in Europe as a combination therapy with a tumor vaccine in patients with advanced melanoma. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Cancer Alcohol Tumor Melanoma Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Liver Disease Therapies For Cancer Fibrotic Disease Lectins Liver Fibrosis Galectin Lactose Combination Therapy Fatty Liver Fatty Liver Disease Galectin 3 Galecto Biotech

    Is GALT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 15 Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
    Sep 30 Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
    Sep 3 Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    Aug 13 Galectin Therapeutics GAAP EPS of -$0.20
    Aug 13 Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
    Aug 1 Galectin Therapeutics appoints Khurram Jamil as chief medical officer
    Aug 1 Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
    Jul 30 Galectin Therapeutics Inc.'s (NASDAQ:GALT) largest shareholders are retail investors with 57% ownership, insiders own 20%
    Jul 24 Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
    Jun 7 Galectin Therapeutics: Neutral On Belapectin For NASH Cirrhosis Amid Financial Challenges
    See more GALT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.2684
    52 Week Low 1.555
    Average Volume 130,332
    200-Day Moving Average 2.53
    50-Day Moving Average 2.64
    20-Day Moving Average 2.60
    10-Day Moving Average 2.54
    Average True Range 0.13
    RSI (14) 42.86
    ADX 22.34
    +DI 17.67
    -DI 15.75
    Chandelier Exit (Long, 3 ATRs) 2.77
    Chandelier Exit (Short, 3 ATRs) 2.84
    Upper Bollinger Bands 2.74
    Lower Bollinger Band 2.45
    Percent B (%b) 0.17
    BandWidth 11.17
    MACD Line -0.04
    MACD Signal Line -0.02
    MACD Histogram -0.0168
    Fundamentals Value
    Market Cap 154.62 Million
    Num Shares 61.8 Million
    EPS -0.76
    Price-to-Earnings (P/E) Ratio -3.29
    Price-to-Sales 0.00
    Price-to-Book 207.70
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.70
    Resistance 3 (R3) 2.70 2.64 2.66
    Resistance 2 (R2) 2.64 2.59 2.64 2.65
    Resistance 1 (R1) 2.57 2.56 2.54 2.57 2.64
    Pivot Point 2.51 2.51 2.50 2.51 2.51
    Support 1 (S1) 2.44 2.46 2.41 2.44 2.36
    Support 2 (S2) 2.38 2.43 2.38 2.35
    Support 3 (S3) 2.31 2.38 2.34
    Support 4 (S4) 2.31